top of page
Executive Spotlights

Bausch & Lomb Seals Deal Acquires Xiidra and Ophthalmology Portfolio from Novartis for $1.7B

Vaughan, ON, June 30, 2023 (Reuters) -- Bausch & Lomb announced a significant move on Friday, with the acquisition of multiple eye-care products from Novartis for a substantial sum of $1.75 billion. As part of the agreement, Bausch + Lomb will take ownership of several valuable assets, including the anti-inflammatory eye drop Xiidra, libvatrep for chronic ocular surface pain, and the rights to utilize Novartis' AcuStream dry-eye drug delivery device.

Read full article here.

Recent Posts

See All

AxoSim appoints Alif Saleh as CEO

New Orleans, LA, June 14, 2024 (Indian Pharma Post) -- AxoSim, a life science firm specializing in lab-grown human brains, has appointed Alif Saleh as its new CEO. Salef, a company builder, brings e


Life Science Headlines
bottom of page